HKEX to launch biotech futures on Nov 28, 2025, tracking 30 Hong Kong-listed firms, with first-six-month levy waiver.

Hong Kong Exchanges and Clearing (HKEX) will launch Hang Seng Biotech Index Futures on November 28, 2025, offering investors a new tool to gain exposure to Hong Kong-listed biotech, pharmaceutical, and medical devices companies eligible for southbound Stock Connect. The futures, tracking 30 major firms, aim to support risk management and investment in a fast-growing sector. HKEX says the launch strengthens Hong Kong’s position as a leading Asia-based derivatives hub. The Securities and Futures Commission’s transaction levy will be waived for the first six months, with margin rates to be announced later. The product will trade on a rolling schedule including the spot month and next three calendar months and quarters.